DrugPatentWatch Database Preview

Claims for Patent: 9,738,905

« Back to Dashboard

Summary for Patent: 9,738,905

Title:	Vector for expressing NC protein of HIV and method for producing NC protein using the same
Abstract:	The present invention relates to a vector for expressing an NC protein of HIV and a method for producing an NC protein using the same. More particularly, the present invention relates to a vector for expressing an NC protein of HIV, in which an intron sequence and an mRNA stability element in the downstream of NC gene are sequentially linked, and a method for producing an NC protein using the same. The vector for expressing an NC protein of HIV of the present invention, in which an intron sequence and an mRNA stability element in the downstream of NC gene are sequentially linked, can express a wild type NC protein in animal cells, and has an effect of improving the expression efficiency, as compared to a known art.
Inventor(s):	You; Ji Chang (Seoul, KR)
Assignee:	You; Ji Chang (Seoul, KR) AVIXGEN INC. (Seoul, KR)
Application Number:	12/520,147
Patent Claims:	1. A vector for expressing a nucleocapsid (NC) protein of Human Immunodeficiency Virus (HIV), comprising a) any one sequence selected from the group consisting of an SV40 19s mRNA intron sequence of SEQ ID NO:8, a modified SV40 16S mRNA intron sequence of SEQ ID NO:9 and a .beta.-globin intron sequence of SEQ ID NO: 10, b) a gene encoding for an HIV NC protein of SEQ. ID NO. 4, selected from the group consisting of SEQ ID NO:3, 5, 6 AND 7, and c) an mRNA stability element wherein the genes of a)-c) are sequentially linked. 2. The vector for expressing an NC protein of HIV according to claim 1, wherein the mRNA stability element is any one selected from the group consisting of RRE (Rev response element), WPRE (woodchuck post-transcriptional regulatory element), .beta.-actin 3'-UTR (untranslated regions) and RSV stability element (Rous sarcoma virus stability element). 3. The vector according to claim 1, wherein the vector for expressing an NC protein of HIV has a cleavage map disclosed in FIG. 2 or FIG. 4. 4. An isolated cell transformed with the vector of any one of claim 2, or 3. 5. The transformed cell according to claim 4, wherein the cell is a COS-7 or 293T cell. 6. A method for producing an NC protein of HIV, comprising the step of culturing the transformed cell of claim 4. 7. A codon-optimized HIV NC polynucleotide for high expression in mammalian cells, comprising a nucleotide sequence represented by any one selected from the group consisting of SEQ. ID NO. 3, SEQ. ID NO. 5, SEQ. ID NO. 6 and SEQ. ID NO. 7.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
South Korea	10-2006-0131392	Dec 20, 2006
South Korea	10-2006-0131393	Dec 20, 2006

PCT Information
PCT Filed	December 20, 2007	PCT Application Number:	PCT/KR2007/006694
PCT Publication Date:	June 26, 2008	PCT Publication Number:	WO2008/075911

Details for Patent 9,738,905

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Schering	INTRON A	interferon alfa-2b	VIAL	103132	001	1986-06-04		You; Ji Chang (Seoul, KR) AVIXGEN INC. (Seoul, KR)	2026-12-20	RX		search
Schering	INTRON A	interferon alfa-2b	VIAL	103132	002	1986-06-04		You; Ji Chang (Seoul, KR) AVIXGEN INC. (Seoul, KR)	2026-12-20	RX		search
Schering	INTRON A	interferon alfa-2b	VIAL	103132	003	1986-06-04		You; Ji Chang (Seoul, KR) AVIXGEN INC. (Seoul, KR)	2026-12-20	RX		search

International Patent Family for US Patent 9,738,905

Country	Patent Number	Publication Date
World Intellectual Property Organization (WIPO)	2008075911	Jun 26, 2008
United States of America	2010047865	Feb 25, 2010
South Korea	101158755	Jun 22, 2012
South Korea	101158756	Jun 22, 2012
South Korea	20080057750	Jun 25, 2008
South Korea	20080057751	Jun 25, 2008
Japan	2010512782	Apr 30, 2010